Now exciting new research from the University of Virginia School of Medicine and the University of Colorado demonstrates the effectiveness of a third strategy: adjusting the landscape of the human body to remove the mechanism that allows pathogens to cause disease.
The researchers have silenced genes within human cells to induce immunity to the parasite E. histolytica, which infects 50 million people and causes 40,000 to 110,000 deaths worldwide each year via severe diarrhea. “This amoeba is a cluster bomb – a voracious killer,” said U.Va.’s ?] Chelsea Marie, a research scientist in infectious diseases and international health, noting the challenge the researchers faced in blocking the amoeba’s ability to kill human cells. “In the back of my mind, I was thinking the parasite was going to decimate the host cells no matter what we did with their genetics.”
The research group used a technique called RNAi to create a library of bladder cancer cells with thousands of independent, silenced genes. Then they challenged these cultures with E. histolytica. “We do this all the time in cancer research,” said Dr. Dan Theodorescu, formerly of U.Va. and now director of the University of Colorado Cancer Center. “Commonly, we’re looking for genes that, when silenced, will make cells more susceptible to chemotherapy.” In this case, the analogue of chemotherapy was the infectious, dangerous pathogen.
E. histolytica proved a stubborn foe, decimating many thousands of the manipulated cell cultures. However, a small number of cells seemed to resist the parasite. Was this the random chance of lucky survival, or had silenced genes somehow provided immunity?
To find out, Marie discarded the dead cells and retested the survivors; again she infected the cells with E. histolytica. “It wasn’t a fluke,” she said. “We did this over nine generations of cells, each time selecting the cells that survived and then re-applying the parasite. Over these generations of selection, we saw the cultures becoming more and more enriched for cells lacking specific genes.”
Using next-generation sequencing, Marie identified the genes that conferred resistance and found that many were involved in managing the flow of potassium into and out of human cells. A follow-up experiment showed that, left unimpeded, E. histolytica caused intestinal cells to pump out potassium directly before cell death.
“We started to see a pretty clear line of reasoning,” Theodorescu said. “The parasite was causing potassium efflux right before cell death, and cells that happened to be unable to transport potassium didn’t die.”
“There is a clear need for new drugs targeting E. histolytica,” said Marie’s mentor, Dr. William A. Petri Jr., chief of U.Va.’s Division of Infectious Diseases and International Health. “Right now there is a single antibiotic that works against this parasite. We know that eventually the parasite will develop resistance to the antibiotic, and at that point there’s no plan B. This could be the plan B – targeting the human genes that enable the parasite to cause disease.”
Marie is pushing forward, working to make the technique used in the study more efficient and move it toward use in humans. But just demonstrating it can work is a huge accomplishment.
“This is a major finding with translational implications for this infection that causes so many deaths worldwide, but also proof that this cancer-science approach can be used to explore genetic mechanisms of resistance in the field of infectious disease,” Theodorescu said.
The findings have been published online by the journal Scientific Reports in an article written by Marie, Hans P. Verkerke, Theodorescu and Petri.